Exhibit 99.1

           CARDIODYNAMICS RECEIVES FDA CLEARANCE FOR FIRST-OF-ITS-KIND
                           ICG DEVICE WITH 12-LEAD ECG

SAN DIEGO, June 21 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the
innovator and leader of Impedance Cardiography (ICG) technology, today announced
that the U.S. Food and Drug Administration (FDA) has granted 510(k) marketing
clearance for the second phase of the BioZ Dx -- the world's first ICG device
with 12-lead electrocardiography (ECG). Market release is expected during July
2005. The BioZ Dx is the result of a co- development partnership between the
Company and Philips Medical Systems and gives physicians the unique ability to
assess the patient's electrical and mechanical cardiovascular status in one
efficient platform. Existing BioZ Dx customers will be able to add the 12-lead
diagnostic ECG capability with a convenient field upgrade.

With just four dual sensors, the ICG portion of the BioZ Dx provides 12
parameters about the heart's pumping ability including the amount of blood
ejected by the heart each minute, the resistance it has to work against, and the
amount of fluid in the chest. This data helps physicians in the assessment,
diagnosis, and treatment of patients with high blood pressure, heart failure,
and shortness of breath. The ECG test is the most common cardiology test
performed worldwide. During the ECG procedure, multiple electrodes measure
electrical signals that the heart emits during each heartbeat. An ECG test can
show a physician evidence of new or previous injury to the heart, heart rhythm
problems, electrical conduction abnormalities, or heart enlargement and signs of
inflammation of the sac surrounding the heart.

Michael K. Perry, CardioDynamics' Chief Executive Officer, stated, "We are very
pleased to receive FDA 510(k) clearance for this phase of our third generation
BioZ monitor. The ECG capability brings the Company's ICG technology closer to
becoming a standard of care now that it is integrated with the commonly used ECG
test. The BioZ Dx ICG/ECG monitor provides our customers with even greater value
and enhanced workflow integration. This achievement is a key milestone for
noninvasive heart monitoring, and we are proud to contribute this latest
advancement to the medical community."

About CardioDynamics:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of
breakthrough medical technology called Impedance Cardiography (ICG). The Company
develops, manufactures and markets noninvasive diagnostic and monitoring
technologies and electrodes. The Company's ICG Systems are being used by
physicians around the world to help battle the number one killer of men and
women -- cardiovascular disease. Partners include GE Healthcare and Philips
Medical Systems. For additional information, please refer to the company's Web
site at www.cdic.com.



Forward-Looking (Safe Harbor) Statement:

Except for the historical and factual information contained herein, this press
release contains forward-looking statements, the accuracy of which is
necessarily subject to uncertainties and risks including the Company's primary
dependence on the BioZ product line, and various uncertainties characteristic of
early growth companies, as well as other risks detailed in the Company's filings
with the SEC, including its 2004 Form 10-K/A. The Company does not undertake to
update the disclosures contained in this press release.

SOURCE  CardioDynamics
     -0-                             06/21/2005
     /CONTACT:  Bonnie Ortega, Investor Relations of CardioDynamics,
+1-800-778-4825, Ext. 1005, or bortega@cardiodynamics.com /
     /Web site:  http://www.cdic.com /